Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients

Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study

“… 29 As Shear et al also pointed out, the percentage difference in reported ISRs between clinical trials and real-life analyses may lie in the different injection conditions and techniques (pre-filled syringe vs auto-injector). 14 Generally, our study showed that even if ISRs symptoms were quite common in real life (51.2% of population experienced at least one symptom related to ISR), involving all different class of biologics, only 3.4% of the surveyed population experienced anxiety or fear of the biologic injection due to ISRs symptoms and no cases of treatment discontinuation or delay was registered.…”

“…However, the sensation of pain at the injection site, for example, might reduce patient adherence. 13 , 14 In this context, it has been shown that biologic selection for psoriasis treatment should take into account numerous factors ranging from disease severity, lesions’ location, comorbidities, as well as patients’ preferences which rely not only on the frequency of drug administration but also on injection site reactions (ISRs) such as swelling at the injection site, pain, burning, erythema, all possibly reducing patient adherence. 15 ISRs are one of the most common side effects of biologics with an incidence rate of 0.5–40%.…”

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

“…Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. 32 , 33 Despite the use of biological drugs and OSM revolutionized the treatment options showing promising results in terms of effectiveness and safety, 34–36 also during the COVID-19 pandemic period which brought further challenges to the daily clinical practice, 37–41 there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of AEs, 8 , 9 phototherapy is often limited by logistic concerns.…”

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

“…[4][5][6][7] On consequence, early diagnosis and appropriate treatment play a key role. 8,9 Even if mild forms of disease are usually treated with topicals, systemic treatments are often required for moderate-to -severe forms of the disease. 10,11 However, conventional systemic drugs (acitretin, cyclosporine, methotrexate, dimethyl fumarate) are often contraindicated or linked to adverse events.…”